Hepatic Arterial Chemoembolization In Combination With Sorafenib For Primary Liver Cancer With Portal Vein Tumor Thrombus

Purpose To explore the treatment effect of Transarterial Chemoembolization combined with sorafenib for patients with Primary liver cancer with portal vein tumor thrombosis.Methods Retrospective analysis in January 2010-December 2012 in guangxi tumor hospital treated 70 cases of PLC with PVTT the patient’s medical record, in which 32 cases combined with conventional sorafenib treatment,38 cases were only treated with conventional TACE. We compared the combined with conventional sorafenib and conventional therapy alone efficient, disease control and cumulative survival, and according to the different parts of PVTT classification, compared with conventional joint sorafenib and prognosis with conventional treatment alone.Results TACE-sorafenib group the total curative effect is superior to the conventional TACE alone with conventional treatment group (RR:31.3% vs 10.5%, compare the difference between groups was statistically significant P= 0.031. DCR:56.2% vs 26.3%, compare the difference between groups was statistically significant P= 0.011. The median survival period 12.0 vs.6.0 months, respectively, P< 0.001). For PVTT subgroup analysis, Ⅰ, Ⅱ Ⅲ type patients with PVTT, TACE-sorafenib curative effect with conventional optimal simply with TACE (P= 0.003, P< 0.001, P= 0.034), but the type Ⅳ PVTT cases the difference of two kinds of treatments of survival and no statistical significance (P = 0.903).Conclusions Hepatic artery chemoembolization (conventional) in combination with sorafenib treatment is a safe and effective method of PLC combined PVTT, merge level or lower for PLC branch of portal vein tumor emboli in the patient-sorafenib combined with conventional scheme with simple compared with conventional can improve overall survival.